Reports indicate that TMB in BRAF‐altered MBC is generally higher, and hence may be a potential biomarker of ICPI efficacy, but larger studies are lacking with regard to the predictive status of BRAF mutations in breast cancer. The gene discussed is BRAF; the disease is breast carcinoma.